Viva Biotech Holdings (HKG:1873)
Hong Kong · Delayed Price · Currency is HKD | Market Cap | 2.71B -49.4% |
| Revenue (ttm) | 2.20B +3.7% |
| Net Income | 205.53M +3.3% |
| EPS | 0.08 +10.3% |
| Shares Out | 2.08B |
| PE Ratio | 16.42 |
| Forward PE | 6.94 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 5,974,000 |
| Open | 1.350 |
| Previous Close | 1.350 |
| Day's Range | 1.280 - 1.350 |
| 52-Week Range | 1.040 - 2.860 |
| Beta | 1.31 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 26, 2026 |
About Viva Biotech Holdings
Viva Biotech Holdings, an investment holding company, engages in the provision of structure-based drug discovery services to biotechnology and pharmaceutical customers worldwide. The company provides discovery biology services, including protein expression, structural biology, hit discovery, bioassay, biomolecular interaction, and pharmacology and DMPK; chemistry services, such as medicinal and synthetic chemistry, purification preparation, and computer-aided drug design services, as well as offers chemical technology platforms; and antibody/bi... [Read more]
Financial Performance
In 2025, Viva Biotech Holdings's revenue was 1.73 billion, a decrease of -12.95% compared to the previous year's 1.99 billion. Earnings were 219.76 million, an increase of 31.36%.
Financial numbers in CNY Financial StatementsNews
Viva Biotech Announces Its 2026 Interim Results: AI Sparks New Paradigm in Drug R&D, CDMO Commercial Manufacturing Accelerates Revenue Growth
HONG KONG, Aug. 26, 2026 /PRNewswire/ -- On August 26, 2026, Viva Biotech Holdings Group ("the Group" or "the Company", stock code: 1873.HK) announced that the Group's revenue amounted to RMB1,006.5 m...
Viva Biotech Announces 2025 Annual Results: AI-Driven Drug Discovery Reinforces Industry Leadership, CDMO Commercial Products Enter Rapid Scale-Up
Financial HighlightsRevenue reached RMB1,729.4 millionGross profit amounted to RMB655.6 millionGross profit margin recorded 37.9%, a YOY increase of 3.3 pp Net profit recorded RMB269.3 million, a YOY ...
Viva Biotech Accelerates AI-Driven Drug Discovery and Advance the 'Lab-in-the-Loop' with NVIDIA
SHANGHAI, March 16, 2026 /PRNewswire/ -- Monday, March 16th at 1:30 PM PT, Viva Biotech (01873.HK) optimizes the Proteina-Complexa model in advancing the design of mini-binders targeting ActRIIA, a re...
Adventures in DMPK: Viva Biotech's One-Stop Pharmacology Platform Cross New Modalities
SHANGHAI , Dec. 29, 2025 /PRNewswire/ -- Drug Pharmacokinetics and Pharmacodynamics (PKPD) has become increasingly critical as drug discovery modalities continue to expand across a broader and more di...
Viva Biotech's invested and incubated company, Arthrosi, has entered into an acquisition agreement with Sobi for a total transaction value of up to US$1.5 billion.
STOCKHOLM , Dec. 15, 2025 /PRNewswire/ -- Swedish Orphan Biovitrum AB (STO: SOBI) recently announced that it has entered into an acquisition agreement with Arthrosi Therapeutics, Inc., which was inves...
Viva Biotech Receives Frost & Sullivan's 2025 APAC Technology Innovation Leadership Recognition in the Integrated Intelligent Drug Discovery Industry
Viva Biotech is acknowledged for its pioneering AI-driven drug discovery platforms that accelerate timelines, reduce costs, and expand therapeutic innovation in the global pharmaceutical R&D ecosystem...
Unlocking the Potential of Cyclic Peptide Therapeutics: Viva Biotech's Discovery Insights
SHANGHAI , Sept. 2, 2025 /PRNewswire/ -- Peptides have recently emerged at the forefront of therapeutic innovation, with cyclic peptides gaining particular attention for their ability to bridge the ga...
Viva Biotech Announces Its 2025 Interim Results: CRO Revenue Returned to Positive Growth, New CDMO Commercialization Projects Showed Promising Growth
Results Highlights for Interim Results ended 30 June 2025 Revenue reached RMB831.9 million Gross profit amounted to RMB339.4 million Gross profit margin was 40.8%, an increase of 6.3 percentage point ...
Viva Biotech's Wholly-Owned Subsidiary Langhua Pharmaceutical Successfully Passes U.S. FDA On-Site Inspection
SHANGHAI, March 28, 2025 /PRNewswire/ -- Zhejiang Langhua Pharmaceutical Co., Ltd. ("Langhua Pharmaceutical"), a wholly-owned subsidiary of Viva Biotech Holdings ("Viva Biotech"), underwent a cGMP (Cu...
Viva Biotech Announces 2024 Annual Results: Significantly Rebounding in Performance with New Stage ahead, AI Leads to a New Era of Novel Drug R&D
Highlights of Annual Results for the Year Ended December 31, 2024 Revenue reached RMB1,986.7 million Gross profit amounted to RMB687.4 million Net profit recorded RMB222.0 million, a significant turna...
Viva Biotech Officially Establishes Boston Branch, Marking Another Milestone in Global Expansion
HONG KONG , Dec. 11, 2024 /PRNewswire/ -- Recently, Viva Biotech Holdings Group ("Viva Biotech") announced the official establishment of its new branch in Boston, USA. As a global leader in drug resea...
Viva Biotech Announces Its 2024 Interim Results: Significant Improvement in Net Profit Growth and Ongoing Optimization of Emerging Technology Platforms
Results Highlights for Interim Results ended 30 June 2024 Revenue reached RMB981.8 million Gross profit amounted to RMB339.1 million Net profit grew by 956.0 YoY to RMB144.2 million Adjusted non-IFRS ...
Viva Biotech (1873.HK) Announces 2023 Annual Results: Successful Implementation of Light-asset Strategy, Achieving Solid Growth and Promising Future
HONG KONG , March 28, 2024 /PRNewswire/ -- Highlights of the Annual Results as of December 31, 2023: Revenue reached RMB2,155.6 million Gross profit amounted to RMB738.5 million Adjusted non-IFRS net ...
Viva Biotech Secures Approximately US$ 210 Million Funding
HONG KONG , Nov. 20, 2023 /PRNewswire/ -- On November 20, 2023, Viva Biotech Holdings Group (1873. HK) announced that it completed a funding round, securing approximately US$210 million and bringing i...
Viva Biotech (1873.HK) Announces 2023 Interim Results: Solid Growth in Main Business, Significant Rebound in Profitability
Highlights of the Interim Results as of June 30, 2023: Revenue reached RMB1,142.2 million, representing a year-on-year increase of approximately 3.0% Gross profit amounted to RMB406.0 million, represe...
Viva Biotech's Portfolio Company Riparian Pharmaceuticals Announces Exclusive License Agreement and Research Agreement with Pfizer for Novel Cardiovascular Programs
WATERTOWN, Mass. , July 20, 2023 /PRNewswire/ -- Riparian Pharmaceuticals, a Viva Biotech portfolio company, is a biotechnology company focused on discovering novel therapeutics for cardiovascular dis...
Viva Biotech's Portfolio Company DTx Pharma Reached the Acquisition Agreement with Novartis
DTx Pharma's Fatty Acid Ligand Conjugated Oligonucleotide (FALCON™) platform facilitates extra-hepatic delivery of siRNA therapeutics Acquisition includes DTx-1252 with the potential to deliver a tran...
Viva Biotech Announced Strategic Investors with an Investment of Approximately US$ 210 Million
HONG KONG , June 16, 2023 /PRNewswire/ -- On June 11, 2023, Viva Biotech Holdings Group (1873.HK) announced that Viva Shanghai, the primary entity for Viva Biotech's CRO business, successfully raised ...
Viva Biotech's Recent Conferences & Events Review
HONG KONG , May 5, 2023 /PRNewswire/ -- In April, Viva Biotech was invited to attend 2022 SAPA-China Annual Conference, 88th API China, Drug Discovery Chemistry, American Association for Cancer Resear...
Viva Biotech Announced 2022 Annual Results:
Revenue amounted to RMB2,379.6 million, representing a year-on-year (YoY) increase of 13.1%.
Focus-X Therapeutics, a Viva Biotech Portfolio Company, Successfully Reached an Acquisition Agreement with Full-Life Technologies
JERSEY CITY, N.J. and SHANGHAI , Dec. 2, 2022 /PRNewswire/ -- Focus-X Therapeutics (referred to here as "Focus-X"), a nuclide drug company that was invested in and incubated by Viva Biotech, successfu...
Viva Biotech Announced 2022 Interim Results
Order Backlog Expected to Empower Future Growth with Increasing Long-term Competitive Advantage s Financial Highlights for the 6 months ended June 30, 2022: Revenue amounted to RMB1,108.7 million, rep...
Viva Biotech Successfully Held The 3rd Annual Partnership Summit
SHANGHAI , June 23, 2022 /PRNewswire/ -- June 16th-20th, 2022 (Beijing time), Viva Biotech 2022 Partnership Summit was successfully held. Over 300 attendees joined the Summit, including founders from ...
Joint Fight Against COVID-19, Viva Biotech Contributes to the Production of the Oral COVID-19 Antiviral Medication and Virus Tests
SHANGHAI, March 18, 2022 /PRNewswire/ -- At present, COVID-19 is still in pandemic status around the world. The superposition of Delta and Omicron variants are rampant, resulting in the continuous enh...
Viva Biotech Announced 2021 Interim Results
Revenue Increased by 419.5% YoY, CRO Business Income Increased by 62.5% YoY, O rder B acklog Recorded a Significant Increase of 72% Financial Highlights for the 6 months ended June 30, 2021: Revenue a...